The 3 analysts offering 12-month price forecasts for Eagle Pharmaceuticals Inc have a median target of 46.00, with a high estimate of 57.00 and a low estimate of 45.00. The median estimate represents a +16.25% increase from the last price of 39.57.
The current consensus among 4 polled investment analysts is to Buy stock in Eagle Pharmaceuticals Inc. This rating has held steady since June, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.28
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.